TNFSF10 and pancreatic neoplasm: In vivo reports revealed that MSC-based delivery of the TRAIL and PTX in the TRAIL-resistant model of pancreatic cancer could restore sensitivity of tumor cell to MSC-delivered TRAIL by suppression of the expression of survival-related genes (Rossignoli et al., 2019).